Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study

The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.

Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · see citing works

Implications of Normal Brain Development for the Pathogenesis of Schizophrenia

Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724 · see citing works

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020 · see citing works

Microglia: Intrinsic immuneffector cell of the brain

Gehrmann, J., Matsumoto, Y., & Kreutzberg, G. W. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(94)00015-h · Cited by 1,111 · see citing works

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,056 · see citing works

A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window

Yrjänheikki, J., Kauppinen, T. M., Keinänen, R., Goldsteins, G., Chan, P. H., & Koıstınaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,040 · see citing works

Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia

Tikka, T., Fiebich, B. L., Goldsteins, G., Keinänen, R., & Koistinaho, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02580.2001 · Cited by 958 · see citing works

Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson’s Disease

Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789 · see citing works

Minocycline Provides Neuroprotection Against N -Methyl- d -aspartate Neurotoxicity by Inhibiting Microglia

Tikka, T., & Koıstınaho, J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7527 · Cited by 530 · see citing works

The Promise of Minocycline in Neurology

Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., & Metz, L. M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00937-8 · Cited by 518 · see citing works

A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases

Amin, A. R., Attur, M. G., Thakker, G. D., Patel, P. D., Vyas, P., Patel, R. N., Patel, I. R., & Abramson, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14014 · Cited by 474 · see citing works

Minocycline Slows Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis

Križ, J., Nguyen, M. D., & Julien, J. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0487 · Cited by 411 · see citing works

Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease

Depino, A. M., Earl, C. D., Kaczmarczyk, E., Ferrari, C. C., Besedovsky, H. O., del Rey, A., Pitossi, F. J., & Oertel, W. H. (2003) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2003.03014.x · Cited by 237 · see citing works

Pharmacokinetic studies on minocycline in man

Macdonald, H., Kelly, R. G., Allen, E. S., Noble, J. F., & Kanegis, L. A. (1973) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1973145852 · Cited by 222 · see citing works

Absence of Neurodegeneration and Neural Injury in the Cerebral Cortex in a Sample of Elderly Patients With Schizophrenia

Arnold, S. E., Trojanowski, J. Q., Gur, R. E., Blackwell, P., Han, L., & Choi, C. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.3.225 · Cited by 199 · see citing works

Schizophrenia: developmental neuroscience and pathobiology

Waddington, J. L. (1993) · The Lancet · doi:10.1016/0140-6736(93)90288-r · Cited by 194 · see citing works

Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS

Zhang, W., Narayanan, M. V., & Friedlander, R. M. (2003) · Annals of Neurology · doi:10.1002/ana.10476 · Cited by 185 · see citing works

The many faces of nitric oxide in schizophrenia. A review

Bernstein, H., Bogerts, B., & Keilhoff, G. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.05.019 · Cited by 179 · see citing works

Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine

Zhang, L., Kitaichi, K., Fujimoto, Y., Nakayama, H., Shimizu, E., Iyo, M., & Hashimoto, K. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.05.015 · Cited by 159 · see citing works

Possible antipsychotic effects of minocycline in patients with schizophrenia

Miyaoka, T., Yasukawa, R., YASUDA, H., Hayashida, M., Inagaki, T., & Horiguchi, J. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.08.013 · Cited by 105 · see citing works

Minocycline and Other Tetracycline Derivatives: A Neuroprotective Strategy in Parkinson’s Disease and Huntington’s Disease

Thomas, M., Le, W. D., & Jankovic, J. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200301000-00005 · Cited by 62 · see citing works

Possible antidepressant effect of minocycline

Levine, J. S., Cholestoy, A., & Zimmerman, J. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.582b · Cited by 60 · see citing works

Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation

Song, Y., Wei, E.-Q., Zhang, W.-P., Ge, Q., Liu, J., Wang, M., Huang, X.-J., Hu, X., & Chen, Z. (2006) · Brain Research · doi:10.1016/j.brainres.2006.02.042 · Cited by 52 · see citing works

Possible anti-catatonic effects of minocycline in patients with schizophrenia

Ahuja, N., & Carroll, B. T. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.01.018 · Cited by 41 · see citing works

Maintained improvement with minocycline of a patient with advanced Huntington's disease

Denovan‐Wright, E. M., Devarajan, S., Dursun, S. M., & Robertson, H. A. (2002) · Journal of Psychopharmacology · doi:10.1177/026988110201600417 · Cited by 29 · see citing works

Minocycline slows progress of Huntington's disease in mice

Berger, A. (2000) · BMJ · doi:10.1136/bmj.321.7253.70 · Cited by 22 · see citing works

Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment

Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00122-9 · Cited by 926 · see citing works

Neuroinflammation and psychiatric illness

Najjar, S., Pearlman, D. M., Alper, K., Najjar, A., & Devinsky, O. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-43 · Cited by 733 · see citing works

Glutamate and dopamine in schizophrenia: An update for the 21 ^st century

Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702 · see citing works

Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition

Wong, M.-L., Inserra, A., Lewis, M. D., Mastronardi, C. A., Leong, L., Choo, J., Kentish, S., Xie, P., Morrison, M., Wesselingh, S. L., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.46 · Cited by 568 · see citing works

Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study

Doorduin, J., de Vries, E. F. J., Willemsen, A. T. M., de Groot, J. C., Dierckx, R., & Klein, H. C. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.066647 · Cited by 561 · see citing works

Cytokines and schizophrenia: microglia hypothesis of schizophrenia

Monji, A., Kato, T., & Kanba, S. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.01945.x · Cited by 508 · see citing works

HPA Axis in the Pathomechanism of depression and schizophrenia: new therapeutic strategies based on its participation

Mikulska, J., Juszczyk, G., Gawrońska-Grzywacz, M., & Herbet, M. (2021) · Brain Sciences · doi:10.3390/brainsci11101298 · Cited by 450 · see citing works

The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia

Na, K., Jung, H., & Kim, Y. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.022 · Cited by 425 · see citing works

A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia

Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04666yel · Cited by 387 · see citing works

Inflammation and Schizophrenia

Kirkpatrick, B. W., & Miller, B. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt141 · Cited by 318 · see citing works

Neuroinflammation in schizophrenia especially focused on the role of microglia

Monji, A., Kato, T. A., Mizoguchi, Y., Horikawa, H., Seki, Y., Kasai, M., Yamauchi, Y., Yamada, S., & Kanba, S. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.12.002 · Cited by 314 · see citing works

Microglial Dysregulation in Psychiatric Disease

Frick, L. R., Williams, K., & Pittenger, C. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/608654 · Cited by 299 · see citing works

Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment

Chaudhry, I. B., Hallak, J. E. C., Husain, N., Minhas, F., Stirling, J., Richardson, P., Dursun, S. M., Dunn, G., & Deakin, J. F. W. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444941 · Cited by 281 · see citing works

Cross talk: the microbiota and neurodevelopmental disorders

Kelly, J. R., Minuto, C., Cryan, J. F., Clarke, G., & Dinan, T. G. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00490 · Cited by 271 · see citing works

Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond

Meyer, U., Schwarz, M., & Müller, N. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.06.003 · Cited by 255 · see citing works

The methodology of TSPO imaging with positron emission tomography

Turkheimer, F. E., Rizzo, G., Bloomfield, P. S., Howes, O., Zanotti-Fregonara, P., Bertoldo, A., & Veronese, M. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150058 · Cited by 238 · see citing works

Evidence for a Dysregulated Immune System in the Etiology of Psychiatric Disorders

Gibney, S. M., & Drexhage, H. A. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9462-8 · Cited by 237 · see citing works

Microglial activation and progressive brain changes in schizophrenia

Laskaris, L., Biase, M. A. D., Everall, I., Chana, G., Christopoulos, A., Skafidas, E. S., Cropley, V., & Pantelis, C. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13364 · Cited by 227 · see citing works

The inflammation hypothesis in geriatric depression

Alexopoulos, G. S., & Morimoto, S. S. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2672 · Cited by 225 · see citing works

Open-label add-on treatment trial of minocycline in fragile X syndrome.

Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-91 · Cited by 223 · see citing works

Microglia Gone Rogue: Impacts on Psychiatric Disorders across the Lifespan

Tay, T. L., Béchade, C., D’Andrea, I., St‐Pierre, M., Henry, M. S., Roumier, A., & Tremblay, M. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00421 · Cited by 211 · see citing works

Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study

Miyaoka, T., Wake, R., Furuya, M., Liaury, K., Ieda, M., Kawakami, K., Tsuchie, K., Taki, M., Ishihara, K., Araki, T., et al. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.02.002 · Cited by 212 · see citing works

Novel therapeutic targets in depression: Minocycline as a candidate treatment

Soczynska, J. K., Mansur, R. B., Brietzke, E. M., Swardfager, W., Kennedy, S. H., Woldeyohannes, H. O., Powell, A. M., Manierka, M. S., & McIntyre, R. S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.07.026 · Cited by 190 · see citing works

Minocycline rescues decrease in neurogenesis, increase in microglia cytokines and deficits in sensorimotor gating in an animal model of schizophrenia

Mattei, D., Djodari-Irani, A., Hadar, R., Pelz, A., de Cossío, L. F., Goetz, T., Matyash, M., Kettenmann, H., Winter, C., & Wolf, S. A. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.01.019 · Cited by 188 · see citing works

Effectiveness and tolerance of anti‐inflammatory drugs' add‐on therapy in major mental disorders: a systematic qualitative review

Fond, G. B., Hamdani, N., Kapczinski, F. P., Boukouaci, W., Drancourt, N., Dargél, A., Oliveira, J., Guen, E. L., Marlinge, E., Tamouza, R., et al. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12211 · Cited by 172 · see citing works

The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial

Deakin, J. F. W., John Suckling, A., Barnes, T. R. E., Byrne, K., Chaudhry, I. B., Dazzan, P., Drake, R., Giordano, A., Husain, N., Jones, P. B., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30345-6 · Cited by 174 · see citing works

The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders

Wen, T. H., Binder, D. K., Ethell, I. M., & Razak, K. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00270 · Cited by 170 · see citing works

Prenatal Immune Challenge in Mice Leads to Partly Sex-Dependent Behavioral, Microglial, and Molecular Abnormalities Associated with Schizophrenia

Hui, C. W., St-Pierre, A., Hajj, H. E., Remy, Y., Hébert, S. S., Luheshi, G. N., Srivastava, L. K., & Tremblay, M. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00013 · Cited by 158 · see citing works

On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death

Kell, D. B., & Pretorius, E. (2015) · Integrative Biology · doi:10.1039/c5ib00158g · Cited by 160 · see citing works

Therapeutic Strategies for Treatment of Inflammation-related Depression

Adžić, M., Brkic, Z., Mitić, M., Francija, E., Jovicic, M. J., Radulović, J., & Marić, N. P. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170828163048 · Cited by 156 · see citing works

Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia

Chew, L.-J., Fusar-Poli, P., & Schmitz, T. (2013) · Developmental Neuroscience · doi:10.1159/000346157 · Cited by 154 · see citing works

Polypharmacy in schizophrenia

Zink, M., Englisch, S., & Meyer‐Lindenberg, A. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3283366427 · Cited by 142 · see citing works

Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial

Liu, F., Guo, X., Wu, R., Ou, J., Zheng, Y., Zhang, B., Xie, L., Zhang, L., Yang, L., Yang, S., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.01.011 · Cited by 135 · see citing works

Methylation Patterns in Whole Blood Correlate With Symptoms in Schizophrenia Patients

Liu, J., Chen, J., Ehrlich, S., Walton, E., White, T. J. H., Perrone‐Bizzozero, N. I., Bustillo, J., Turner, J. A., & Calhoun, V. D. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt080 · Cited by 134 · see citing works

Minocycline: Therapeutic Potential in Psychiatry

Dean, O. M., Data-Franco, J., Giorlando, F., & Berk, M. (2012) · CNS Drugs · doi:10.2165/11632000-000000000-00000 · Cited by 131 · see citing works

The role of the gut microbiome in the development of schizophrenia

Kelly, J. R., Minuto, C., Cryan, J. F., Clarke, G. A., & Dinan, T. G. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.02.010 · Cited by 119 · see citing works

Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.

Khodaie-Ardakani, M.-R., Mirshafiee, O., Farokhnia, M., Tajdini, M., Hosseini, S.-M.-R., Modabbernia, A., Rezaei, F., Salehi, B., Yekehtaz, H., Ashrafi, M., et al. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.051 · Cited by 104 · see citing works

Putative neuroprotective agents in neuropsychiatric disorders

Dodd, S., Maes, M. H. J., Anderson, G., Dean, O. M., Moylan, S., & Berk, M. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.11.007 · Cited by 105 · see citing works

Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms

Kelly, D. L., Sullivan, K. M., McEvoy, J. P., McMahon, R. P., Wehring, H. J., Gold, J. M., Liu, F., Warfel, D. T., Vyas, G. R., Richardson, C. M., et al. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000345 · Cited by 102 · see citing works

The interplay of dopamine metabolism abnormalities and mitochondrial defects in the pathogenesis of schizophrenia

Xu, H., & Yang, F. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02233-0 · Cited by 101 · see citing works

The cannabinoid system and microglia in health and disease

Duffy, S. S., Hayes, J. P., Fiore, N. T., & Moalem‐Taylor, G. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108555 · Cited by 96 · see citing works

Minocycline in neurodegenerative and psychiatric diseases: An update

Romero‐Miguel, D., Lamanna‐Rama, N., Casquero‐Veiga, M., Gómez‐Rangel, V., Desco, M., & Soto‐Montenegro, M. L. (2020) · European Journal of Neurology · doi:10.1111/ene.14642 · Cited by 95 · see citing works

Minocycline alleviates behavioral deficits and inhibits microglial activation in the offspring of pregnant mice after administration of polyriboinosinic–polyribocytidilic acid

Zhu, F., Zheng, Y., Liu, Y. H., Zhang, X., & Zhao, J. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.06.046 · Cited by 87 · see citing works

Evidence for an Immune Role on Cognition in Schizophrenia: A Systematic Review

Ribeiro-Santos, R., Teixeira, A. L., & Salgado, J. V. (2014) · Current Neuropharmacology · doi:10.2174/1570159x1203140511160832 · Cited by 86 · see citing works

GABA receptor subunit distribution and FMRP–mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism

Fatemi, S. H., & Folsom, T. D. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.10.010 · Cited by 85 · see citing works

Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials

Xiang, Y.-Q., Zheng, W., Wang, S.-B., Yang, X.-H., Cai, D.-B., Ng, C. H., Ungvari, G. S., Kelly, D. L., Xu, W.-Y., & Xiang, Y.-T. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.11.012 · Cited by 83 · see citing works

Minocycline in Acne Vulgaris

Ochsendorf, F. R. (2010) · American Journal of Clinical Dermatology · doi:10.2165/11319280-000000000-00000 · Cited by 80 · see citing works

Are the emergence of affective disturbances in neuropathic pain states contingent on supraspinal neuroinflammation?

Fiore, N. T., & Austin, P. J. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.04.012 · Cited by 80 · see citing works

Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia

Solmi, M., Veronese, N., Thapa, N., Facchini, S., Stubbs, B., Fornaro, M., Carvalho, A. F., & Correll, C. U. (2017) · CNS Spectrums · doi:10.1017/s1092852916000638 · Cited by 78 · see citing works

Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients

Emadi-Kouchak, H., Mohammadinejad, P., Asadollahi‐Amin, A., Rasoulinejad, M., Zeinoddini, A., Yalda, A., & Akhondzadeh, S. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000098 · Cited by 76 · see citing works

The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action

Wong, E. H. F., Tarazi, F. I., & Shahid, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.001 · Cited by 75 · see citing works

Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2×2 clinical trial

Savitz, J. B., Preskorn, S., Teague, T. K., Drevets, D. A., Yates, W. R., & Drevets, W. (2012) · BMJ Open · doi:10.1136/bmjopen-2011-000643 · Cited by 72 · see citing works

Structural and Functional Deviations of the Hippocampus in Schizophrenia and Schizophrenia Animal Models

Wegrzyn, D., Juckel, G., & Faissner, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105482 · Cited by 73 · see citing works

Clinical management of negative symptoms of schizophrenia: An update

Tsapakis, E.-M., Dimopoulou, T., & Tarazi, F. I. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.008 · Cited by 72 · see citing works

Anti-inflammatory signaling in schizophrenia

Meyer, U. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.05.014 · Cited by 72 · see citing works

Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions

Drouin‐Ouellet, J., Brownell, A., Saint‐Pierre, M., Fasano, C., Émond, V., Trudeau, L., Lévesque, D., & Cicchetti, F. (2010) · Glia · doi:10.1002/glia.21086 · Cited by 72 · see citing works

Resolving and Rescuing Developmental Miswiring in a Mouse Model of Cognitive Impairment

Chini, M., Pöpplau, J. A., Lindemann, C., Carol-Perdiguer, L., Hnida, M., Oberlander, V. C., Xu, X., Ahlbeck, J., Bitzenhofer, S. H., Mulert, C., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.09.042 · Cited by 68 · see citing works

The Neuroimmunology of Schizophrenia

Annya, M., Smyth, Stephen, M., & Lawrie, S. M. (2013) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2013.11.3.107 · Cited by 66 · see citing works

Annual Research Review: The neuroinflammation hypothesis for stress and psychopathology in children – developmental psychoneuroimmunology

O’Connor, T. G., Moynihan, J. A., & Caserta, M. T. (2013) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12187 · Cited by 64 · see citing works

Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update

Chaves, C., de Marque, C. R., Trzesniak, C. M. F., de Sousa, J. P. M., Zuardi, A. W., Crippa, J. A. S., Dursun, S. M., & Hallak, J. E. C. (2009) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2009001100002 · Cited by 64 · see citing works

Aripiprazole inhibits superoxide generation from phorbol-myristate-acetate (PMA)-stimulated microglia in vitro: Implication for antioxidative psychotropic actions via microglia

Kato, T. A., Monji, A., Yasukawa, K., Mizoguchi, Y., Horikawa, H., Seki, Y., Hashioka, S., Han, Y.-H., Kasai, M., Sonoda, N., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.03.019 · Cited by 62 · see citing works

Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial

Dean, O. M., Maes, M., Ashton, M., Berk, L., Kanchanatawan, B., Sughondhabirom, A., Tangwongchai, S., Ng, C., Dowling, N., Malhi, G. S., et al. (2014) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2014.12.3.180 · Cited by 58 · see citing works

Morphological features of microglial cells in the hippocampal dentate gyrus of Gunn rat: a possible schizophrenia animal model

Liaury, K., Miyaoka, T., Tsumori, T., Furuya, M., Wake, R., Ieda, M., Tsuchie, K., Taki, M., Ishihara, K., Tanra, A. J., et al. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-56 · Cited by 56 · see citing works

Adjunct Treatments for Schizophrenia and Bipolar Disorder: What to Try When You Are Out of Ideas

Torrey, E. F., & Davis, J. M. (2011) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.5.4.5 · Cited by 56 · see citing works

The antibiotic minocycline prevents methamphetamine-induced rewarding effects in mice

Fujita, Y., Kunitachi, S., Iyo, M., & Hashimoto, K. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.01.005 · Cited by 56 · see citing works

Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia

Prestwood, T. R., Asgariroozbehani, R., Wu, S., Agarwal, S. M., Logan, R. W., Ballon, J. S., Hahn, M., & Freyberg, Z. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113101 · Cited by 58 · see citing works

Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial

Ghaleiha, A., Alikhani, R., Kazemi, M.-R., Mohammadi, M.-R., Mohammadinejad, P., Zeinoddini, A., Hamedi, M., Shahriari, M., Keshavarzi, Z., & Akhondzadeh, S. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0175 · Cited by 56 · see citing works

Doxycycline prevents and reverses schizophrenic-like behaviors induced by ketamine in mice via modulation of oxidative, nitrergic and cholinergic pathways

Ben‐Azu, B., Omogbiya, I. A., Aderibigbe, A. O., Umukoro, S., Ajayi, A. M., & Iwalewa, E. O. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.02.007 · Cited by 52 · see citing works

Autoimmune phenotypes in schizophrenia reveal novel treatment targets

Severance, E. G., Dickerson, F., & Yolken, R. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.005 · Cited by 52 · see citing works

Introducing directly induced microglia-like (iMG) cells from fresh human monocytes: a novel translational research tool for psychiatric disorders

Ohgidani, M., Kato, T. A., & Kanba, S. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00184 · Cited by 49 · see citing works

Minocycline affects cocaine sensitization in mice

Chen, H., Uz, T., & Manev, H. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.01.078 · Cited by 49 · see citing works

The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial

Weiser, M., Levi, L. W., Burshtein, S., Chiriță, R., Cirjaliu, D., Gonen, I., Yolken, R. H., Davidson, M., Zamora, D., & Davis, J. M. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.10.023 · Cited by 48 · see citing works

Use of Yokukansan (TJ‐54) in the treatment of neurological disorders: a review

de Caires, S., & Steenkamp, V. (2010) · Phytotherapy Research · doi:10.1002/ptr.3146 · Cited by 45 · see citing works

Profile of minocycline and its potential in the treatment of schizophrenia

Zhang, L., & Zhao, J. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s64236 · Cited by 45 · see citing works

Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms

Kelly, D. L., Vyas, G. R., Richardson, C. M., Koola, M. M., McMahon, R. P., Buchanan, R. W., & Wehring, H. J. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.08.005 · Cited by 44 · see citing works

Microglial functional alteration and increased diversity in the challenged brain: Insights into novel targets for intervention

Tremblay, M.-È. (2021) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2021.100301 · Cited by 42 · see citing works

Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia

Chaves, C., Marque, C. R., Maia-de-Oliveira, J. P., Wichert-Ana, L., Ferrari, T. B., Santos, A. C., Araújo, D., Machado-de-Sousa, J. P., Bressan, R. A., Elkis, H., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.11.031 · Cited by 41 · see citing works

Minocycline improves recognition memory and attenuates microglial activation in Gunn rat: A possible hyperbilirubinemia-induced animal model of schizophrenia

Liaury, K., Miyaoka, T., Tsumori, T., Furuya, M., Hashioka, S., Wake, R., Tsuchie, K., Fukushima, M., Limoa, E., Tanra, A. J., et al. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.12.017 · Cited by 40 · see citing works

Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia

Tufvesson‐Alm, M., Schwieler, L., Schwarcz, R. M., Goiny, M., Erhardt, S., & Engberg, G. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.003 · Cited by 40 · see citing works

Minocycline Does Not Decrease Intensity of Neuropathic Pain, but Improves Its Affective Dimension

Sumitani, M., Ueda, H., Hozumi, J., Inoue, R., Kogure, T., Ogata, T., & Yamada, Y. (2015) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.3109/15360288.2014.1003674 · Cited by 37 · see citing works

Adjunctive minocycline for major mental disorders: A systematic review

Zheng, W., Zhu, X., Zhang, Q., Cheng, G., Cai, D.-B., He, J., Ng, C. H., Ungvari, G. S., Peng, X.-J., Ning, Y., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119858286 · Cited by 37 · see citing works

Microglial activation in schizophrenia and minocycline treatment

Hashimoto, K. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.06.012 · Cited by 35 · see citing works

Glutamatergic agents for schizophrenia: current evidence and perspectives

Zink, M., & Correll, C. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1040393 · Cited by 36 · see citing works

Neuroinflammation and oxidative stress in schizophrenia: are these opportunities for repurposing?

Ansari, Z., Pawar, S. R., & Seetharaman, R. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.2006514 · Cited by 35 · see citing works

Minocycline Modulates Human Social Decision-Making: Possible Impact of Microglia on Personality-Oriented Social Behaviors

Kato, T. A., Watabe, M., Tsuboi, S., Ishikawa, K., Hashiya, K., Monji, A., Utsumi, H., & Kanba, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040461 · Cited by 34 · see citing works

A case of methamphetamine use disorder treated with the antibiotic drug minocycline

Tanibuchi, Y., Shimagami, M., Fukami, G., Sekine, Y., Iyo, M., & Hashimoto, K. (2010) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2009.12.005 · Cited by 33 · see citing works

Deep rTMS Mitigates Behavioral and Neuropathologic Anomalies in Cuprizone-Exposed Mice Through Reducing Microglial Proinflammatory Cytokines

Yang, L., Su, Y.-W., Guo, F., Zhang, H.-D., Zhao, Y., Huang, Q., & Xu, H.-Y. (2020) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2020.556839 · Cited by 33 · see citing works

Beyond Dopamine: Glutamate as a Target for Future Antipsychotics

Sendt, K.-V., Giaroli, G., & Tracy, D. K. (2012) · ISRN Pharmacology · doi:10.5402/2012/427267 · Cited by 33 · see citing works

Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia

Ohnuma, T., & Arai, H. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.08.027 · Cited by 31 · see citing works

Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study

Ardakani, M. R. K., Seddighi, S., Modabbernia, A., Rezaei, F., Salehi, B., Ashrafi, M., Shams‐Alizadeh, N., Mohammad-karimi, M., Esfandiari, G.-R., Hajiaghaee, R., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.01.011 · Cited by 29 · see citing works

l-lysine as an adjunct to risperidone in patients with chronic schizophrenia: A double-blind, placebo-controlled, randomized trial

Zeinoddini, A., Ahadi, M., Farokhnia, M., Rezaei, F., Tabrizi, M. H., & Akhondzadeh, S. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.08.016 · Cited by 27 · see citing works

L-lysine as adjunctive treatment in patients with schizophrenia: a single-blinded, randomized, cross-over pilot study

Wass, C., Klamer, D., Katsarogiannis, E., Pålsson, E., Svensson, L., Fejgin, K., Bogren, I.-B., Engel, J. A., & Rembeck, B. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-40 · Cited by 25 · see citing works

Functional neuroimaging of minocycline's effect in a patient with schizophrenia

Chaves, C., de Marque, C. R., Wichert‐Ana, L., Maia‐de‐Oliveira, J. P., Itikawa, E. N., Crippa, J. A. S., Zuardi, A. W., Todd, K. G., Baker, G. B., Dursun, S. M., et al. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.01.020 · Cited by 23 · see citing works

Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia

Qurashi, I., Collins, J., Chaudhry, I. B., & Husain, N. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114527358 · Cited by 22 · see citing works

Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia

Lago, S. G., & Bahn, S. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00205 · Cited by 22 · see citing works

Systematic Review of the Therapeutic Role of Apoptotic Inhibitors in Neurodegeneration and Their Potential Use in Schizophrenia

Morén, C., Treder, N., Martínez-Pinteño, A., Rodríguez, N., Arbelo, N., Madero, S., Gómez, M., Mas, S., Gassó, P., & Parellada, E. (2022) · Antioxidants · doi:10.3390/antiox11112275 · Cited by 20 · see citing works

Immunomodulatory Effects of Clozapine: More Than Just a Side Effect in Schizophrenia

Amerio, A., Magnani, L., Arduino, G., Fesce, F., de Filippis, R., Parise, A., Costanza, A., Nguyen, K. D., Saverino, D., Berardis, D. D., et al. (2023) · Current Neuropharmacology · doi:10.2174/1570159x22666231128101725 · Cited by 21 · see citing works

Minocycline decreases CD36 and increases CD44 in LPS-induced microglia

Hashemi-monfared, A., Firouzi, M., Bahrami, Z., Zahednasab, H., & Harirchian, M. H. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.01.010 · Cited by 19 · see citing works

Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial

Fekadu, A., Mesfin, M., Medhin, G., Alem, A., Teferra, S., Gebre-Eyesus, T., Seboxa, T., Assefa, A., Hussein, J., Lemma, M. T., et al. (2013) · Trials · doi:10.1186/1745-6215-14-406 · Cited by 19 · see citing works

Neuro‐Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets

Guo, X., Liu, H. N., Song, Y., Wang, J., Liu, D., Zheng, Z., Li, J., Li, B., Song, A., He, W., et al. (2026) · MedComm · doi:10.1002/mco2.70497 · Cited by 21 · see citing works

Minocycline for Schizophrenia: A critical review

Miyaoka, T. (2012) · Open Journal of Psychiatry · doi:10.4236/ojpsych.2012.224056 · Cited by 8 · see citing works

Clinical Potential of Minocycline for Schizophrenia

Miyaoka, T. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708786441858 · Cited by 38 · see citing works

Minocycline as adjunct therapy for a male patient with deficit schizophrenia

Chen, X., Xiong, Z., Li, Z., Yang, Y., Zheng, Z., Li, Y., Xie, Y., & Li, Z. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s179658 · Cited by 9 · see citing works

Adjunctive minocycline in clozapine and amisulpride treated schizophrenia patients with persistent symptoms

Tzavellas, E., Karaiskos, D., Konstantinou, J., Oikonomou, E. K., Soldatos, R. F., & Paparrigopoulos, T. J. (2017) · European Psychiatry · doi:10.1016/j.eurpsy.2017.01.1663

Minocycline as Add-On Treatment Decreases the Negative Symptoms of Schizophrenia; A Randomized Placebo-Controlled Clinical Trial

Ghanizadeh, A. J., Dehbozorgi, S., OmraniSigaroodi, M., & Rezaei, Z. (2014) · Recent Patents on Inflammation & Allergy Drug Discovery · doi:10.2174/1872213x08666141029123524 · Cited by 42 · see citing works